Frontlight ResearchEarly access
CompletedPhase 4
Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
Key facts
- Who runs it
- Duke University
- Where
- Atlanta, Cleveland, Phoenix, Pittsburgh, South Euclid, St Louis, and Tempe, United StatesSee the 8 sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 455 people enrolled
- Started
- 25 Sept 2023
- Ended
- 17 May 2024
- Type of study
- Interventional, 3 groups
- Treatments tested
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
- Sequential Vaccination (Influenza vaccine then mRNA COVID booster)
- Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
- Record updated
- 13 June 2025
Who can take part
- Age
- 6 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Healthy children aged 6-11 years and healthy adults aged 18-64 years that have not received the current season's influenza vaccination or a mRNA COVID-19 vaccination in the past 6 months and have already completed at least a two-dose primary series of an mRNA COVID-19 vaccination
- English or Spanish literate
- Email or text message capability for weekly follow-up
- Intention of receiving influenza vaccine and mRNA COVID-19 vaccine based on ACIP-CDC guidelines
- Willing to provide written/electronic informed consent
- Intention of being available for entire study period and able to complete all relevant study procedures, including follow-up phone calls and clinic visits
Who cannot take part
- Self-reported COVID-19 infection within 3 months prior to enrollment
- Received COVID-19 vaccine within 6 months prior to enrollment
- Received influenza vaccine during the respective influenza season in which the participants are being enrolled
- History of severe allergic reaction after a previous dose of any influenza or COVID-19 mRNA vaccine; or to an influenza or COVID-19 mRNA vaccine component
- Receipt of any licensed vaccine within 6 weeks prior to enrollment in this study or planning receipt of any vaccines within 4 weeks after the receipt of the second vaccine dose administered during study procedures
- Has an immunocompromising condition or taking immunosuppressive medication*; Received oral, intramuscular or intravenous systemic immunosuppressants, or immune modifying drugs for >14 days in total within 6 months prior to any study vaccine dose (for corticosteroids ≥ 20 mg/day of prednisone equivalent); ** Note: Topical medications are allowed
- Received immunoglobulin, SARS-CoV-2 immunoglobulin, SARS-CoV-2 monoclonal antibody, or blood-derived products, within 3 months prior any study vaccine dose
- Temporary Delay Criteria: History of febrile illness (> 100.0°F or 37.8°C) within the past 72 hours prior to vaccine administration
- History of Guillain-Barré syndrome
- History of myocarditis or pericarditis
- History of multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A)
- Bleeding disorder diagnosed by a healthcare provider or bleeding difficulties with intramuscular injections or blood draws
- Any condition which, in the opinion of the investigators, may pose a health risk to the participant or interfere with the evaluation of the study objectives
- < 9 years of age and recommended to receive two doses of IIV4 during the respective influenza season in which they are being enrolled
- Currently pregnant, planning to become pregnant within the first three months of the study per participant self-report or likely to be pregnant per screening criteria
- Has injury or other reason why deltoid site on both arms cannot be used for vaccinations
Where in United States
- Centers for Disease Control and PreventionAtlanta, United States
- University Hospitals Cleveland Medical Center*Cleveland, United States
- VA Northeast Ohio Healthcare System (VANEOHS)Cleveland, United States
- Valleywise Health Comprehensive Health CenterPhoenix, United States
- Department of Family Medicine, University of Pittsburgh School of MedicinePittsburgh, United States
- Senders PediatricsSouth Euclid, United States
- Washington University IDCRUSt Louis, United States
- ASU Biodesign InstituteTempe, United States
About the trial
What the trial wants to find out
This is a prospective, randomized randomized immunologic study of response to influenza and SARS-CoV-2 vaccination across four of the US Influenza Vaccine Effectiveness (Flu VE) Network study sites.
The 3 groups in the trial
- Group i: Concomitant VaccinationTreatment being tested
Concomitant Vaccination (Influenza vaccine and mRNA COVID booster) at Visit 1
Treatment: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
- Group ii: Influenza Vaccination at Visit 1Treatment being tested
Sequential vaccination with Influenza vaccination at Visit 1 and mRNA COVID booster at Visit 2
Treatment: Sequential Vaccination (Influenza vaccine then mRNA COVID booster)
- Group iii: mRNA COVID-19 Vaccination at Visit 1Treatment being tested
Sequential vaccination with mRNA COVID booster at Visit 1 and Influenza vaccination at Visit 2
Treatment: Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Study of the Immunogenicity and Duration of Antibody Response Against Circulating SARS-CoV-2 Variant and Influenza Viruses Following Concomitant Versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Cell Culture-based Influenza Vaccine Among Children and Adults
- Record updated
- 13 June 2025